Core Viewpoint - Jiuan Medical announced a share buyback plan, indicating a strategic move to enhance shareholder value and confidence in the company's future performance [1] Group 1 - As of October 21, 2025, the company has repurchased a total of 5,076,901 shares [1] - The repurchased shares represent 1.09% of the company's current total share capital [1]

Group 1 - The core point of the article is that Tianjin Jiuan Medical Electronics Co., Ltd. has disclosed its share repurchase progress, indicating that as of October 21, 2025, the company has repurchased shares amounting to 1.09% of its total share capital, with a total expenditure of approximately 204 million yuan [1][3]. Group 2 - Background of the repurchase plan: The company plans to invest between 300 million yuan and 600 million yuan to repurchase shares, with a maximum price of 53.5 yuan per share [2]. - Progress of the repurchase: As of October 21, 2025, the company has repurchased a total of 5,076,901 shares at prices ranging from 39.83 yuan to 40.883 yuan per share, totaling approximately 204 million yuan [3]. - Future plans: The company will continue to implement the repurchase plan based on market conditions and will comply with relevant legal disclosure obligations [4].

证券代码：002432 证券简称：九安医疗 公告编号：2025-081 天津九安医疗电子股份有限公司 关于回购公司股份比例达到1%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年10月13日召 开了第六届董事会第二十七次会议，审议并通过了《关于公司回购股份方案的议 案》。本次回购资金来源为公司自有资金及回购专项贷资金，回购的资金总额不 低于3亿元人民币（含）且不超过6亿元人民币（含），回购股份的价格为不超过 人民币53.5元/股（含），具体回购数量以回购期限届满时实际回购的股份数量为 准。具体回购方案详见公司2025年10月14日在《证券时报》和巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于回购公司股份方案暨取得股票回购专 项贷款承诺函的公告》（公告编号：2025-075）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9号—回购股份》等相关规定，回购期间，回购股份占上市公司总股本的比例每 增加1%的，应当在事实发生之日起三个交易日内予 ...

Core Viewpoint - The company is focused on accelerating the implementation of its "O+O" new model for diabetes diagnosis and care in China and the United States, while also aiming to develop "blockbuster products" in the CGM and internet healthcare sectors [1] Group 1: Strategic Focus - The company is committed to building a competitive edge in the Continuous Glucose Monitoring (CGM) field and is open to considering mergers and acquisitions (M&A) or strategic investments in companies with key technological capabilities [1] - The company emphasizes the importance of aligning with partners that share its business philosophy and values, indicating a cautious approach to M&A in non-core areas [1] Group 2: Market Opportunities - The company recognizes the broad prospects in its main business areas, particularly in CGM and internet healthcare, and is actively seeking suitable opportunities for growth [1] - The company acknowledges the need for patience in identifying good acquisition targets, highlighting the challenges and costs associated with entering non-core industries [1]

Group 1 - The company, Ji'an Medical, is actively investing in the pan-technology sector through partnerships with professional investors [2]

Core Viewpoint - The company, Ji'an Medical (002432), has indicated that it will provide information regarding the number of shareholders as of September 2025 in its third-quarter report for that year [1] Group 1 - The company responded to investor inquiries on October 17 regarding future shareholder numbers [1]

Core Viewpoint - Ji'an Medical (002432) reported that as of October 10, 2025, the number of shareholders is approximately 72,100 [1] Group 1 - The company has engaged with investors through an interactive platform [1] - The reported number of shareholders indicates a significant level of investor interest in the company [1]

Core Viewpoint - On October 16, Jiuan Medical experienced a 1.29% increase in stock price with a trading volume of 537 million yuan, indicating strong market interest and activity in the company's shares [1]. Financing Summary - On October 16, Jiuan Medical had a financing purchase amount of 63.86 million yuan and a financing repayment of 55.10 million yuan, resulting in a net financing purchase of 8.76 million yuan. The total financing and securities balance reached 1.21 billion yuan [1]. - The current financing balance of 1.20 billion yuan accounts for 6.34% of the circulating market value, which is above the 80th percentile level over the past year, indicating a high level of financing activity [1]. - In terms of securities lending, Jiuan Medical repaid 2,000 shares and sold 5,000 shares on October 16, with a selling amount of 203,900 yuan. The remaining securities lending volume is 244,300 shares, with a balance of 9.96 million yuan, also exceeding the 90th percentile level over the past year [1]. Business Performance - As of September 19, Jiuan Medical had 72,000 shareholders, a decrease of 1.50% from the previous period, while the average circulating shares per person increased by 1.53% to 6,582 shares [2]. - For the first half of 2025, Jiuan Medical reported a revenue of 765 million yuan, a year-on-year decrease of 43.35%, while the net profit attributable to the parent company was 920 million yuan, reflecting a year-on-year increase of 52.91% [2]. Dividend and Shareholding Structure - Since its A-share listing, Jiuan Medical has distributed a total of 1.794 billion yuan in dividends, with 1.39 billion yuan distributed over the past three years [3]. - As of June 30, 2025, among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 10.99 million shares, a decrease of 1.836 million shares from the previous period. The Southern Zhongzheng 500 ETF held 4.936 million shares, down by 128,100 shares. Hong Kong Central Clearing Limited entered the top ten shareholders with 2.7895 million shares [3].

Core Viewpoint - The company, Jiann Medical (九安医疗), has announced that it will disclose its Q3 2025 financial report on October 25, 2025, and has not provided any preliminary performance forecasts for the current quarter [1] Group 1 - Investors inquired about the performance comparison of Q3 2025 with the same period last year, specifically whether there was growth or decline [1] - Jiann Medical confirmed the scheduled disclosure date for its Q3 2025 report, indicating that detailed operational and financial information will be available at that time [1]

公司 2024 年员工持股计划管理委员会委员施向健先生因个人原因，申请辞 去管理委员会委员职务。根据公司《2024 年员工持股计划管理办法》的相关规 定，本次持有人会议同意补选马志国先生为公司 2024 年员工持股计划管理委员 会委员，任期与本次员工持股计划存续期一致。 马志国先生未在公司担任董事、监事、高级管理人员职务，未在公司第一大 股东单位担任职务，与持有公司 5%以上股东、实际控制人、公司董事、监事、 高级管理人员不存在关联关系。 证券代码：002432 证券简称：九安医疗 公告编号：2025-080 天津九安医疗电子股份有限公司 2024年员工持股计划第二次持有人会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日 在公司会议室以现场结合通讯方式召开 2024 年员工持股计划第二次持有人会议。 本次会议通知已于 2025 年 10 月 11 日以通讯方式发出。本次会议由公司 2024 年员工持股计划管理委员会召集，由管理委员会主任张飞先生主持。本次应参会 持 ...